Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and …
TF Tsai, Y Tada, C Kung, Y Zhong… - The Journal of …, 2024 - Wiley Online Library
Expanding the systemic treatment options for patients with psoriasis, deucravacitinib, an
oral, selective, allosteric tyrosine kinase 2 inhibitor is approved in the United States …
oral, selective, allosteric tyrosine kinase 2 inhibitor is approved in the United States …
Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program
LF Lincheta, YS Nápoles, ORG Lovio… - International …, 2024 - Elsevier
Itolizumab is a humanized monoclonal antibody that selectively targets the CD6-ALCAM
pathway. This article reports on the safety and efficacy of itolizumab in the treatment of …
pathway. This article reports on the safety and efficacy of itolizumab in the treatment of …
Uticaj različitih efekata terapijskih modaliteta na kvalitet života pacijenata sa psorijazom
A Milidrag - Универзитет у Крагујевцу, 2023 - nardus.mpn.gov.rs
Uvod: Studija je imala za cilj proceniti kvalitetu života pacijenata obolelih od psorijaze, te
istražiti razlike u zavisnosti od vrste primenjivanog terapijskog modaliteta (biološka …
istražiti razlike u zavisnosti od vrste primenjivanog terapijskog modaliteta (biološka …